Evidence map›Paper›PMID 33484225›Full record

ReviewNeurogastroenterology and motility2021

Deconstructing stigma as a barrier to treating DGBI: Lessons for clinicians.

Jordyn H Feingold, Douglas A Drossman

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Neurogastroenterology and motility, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05107999 (Stigma and Efficacy of Zhizhu Kuanzhong Capsules Versus Doxepin in the Treatment of Refractory Functional Dyspepsia), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05107999 naunknown statusnot on this map

Stigma and Efficacy of Zhizhu Kuanzhong Capsules Versus Doxepin in the Treatment of Refractory Functional Dyspepsia: a Randomized Controlled Trial

TypeinterventionalSponsorRenJi HospitalRan2021 to 2022Enrolled76ConditionsFunctional Gastrointestinal Disorders, Dyspepsia, Psychosomatic DisorderArmsZhizhu Kuanzhong capsules (ZZKZ), Doxepin Hydrochloride (Doxepin)
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Transitions of care for adolescents with disorders of gut-brain interaction.Journal of pediatric gastroenterology and nutrition · 2024
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jordyn H FeingoldDepartment of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-4658-1520
Douglas A DrossmanCenter for Education and Practice of Biopsychosocial Care, UNC Center for Functional GI and Motility Disorders and Drossman Gastroenterology, Chapel Hill, NC, USA.ORCID 0000-0002-8178-0453
Icahn School of Medicine at Mount Sinai · USUniversity of North Carolina Health Care · US

Funding

Conduits: MSHS Translational Science HubTL1TR001434 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GABRILOVE, JANICE L · 2015 to 2019
$2.1M
NCATS NIH HHS TL1 TR001434
6 · The paper itself

Abstract

Stigma, defined as social devaluation based on negative stereotypes toward a particular population, is prevalent within health care and is a common phenomenon in disorders of gut-brain interaction (DGBI). Characteristically, DGBI including functional dyspepsia (FD) lack a structural etiology to explain symptoms, have high psychiatric co-morbidity, and respond to neuromodulators traditionally used to treat psychopathology. As a result, these disorders are frequently and wrongly presumed to be psychiatric and carry a great deal of stigma. Stigma has profound adverse consequences for patients, including emotional distress, medication non-adherence, barriers to accessing care, and increased symptoms. The basis for stigma dates back to the 17th Century concept of mind-body dualism. Patients and health care providers need to understand the factors that promote stigma and methods to ameliorate it. In this minireview, we address the data presented in Yan et al.'s (Neurogastroenterol Motil, 2020, e13956). We offer concrete solutions for clinicians to mitigate the impact of stigma to optimize treatment adherence and clinical outcomes for patients with DGBI.

Indexed as

Gastrointestinal DiseasesSocial StigmaHumansantidepressantsdisorders of gut-brain interactionfunctional dyspepsianeuromodulatorspatient-doctor communicationstigma

Identifiers

PMID33484225
PMCPMC8091160
OpenAlexW3122942910

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.